UCI 05-46:A Phase II Study of AlbuminBound-Paclitaxel (Abraxane) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression.

Trial Profile

UCI 05-46:A Phase II Study of AlbuminBound-Paclitaxel (Abraxane) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Paclitaxel (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 12 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 31 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top